| Outcome Measures: |
Primary: Assessment of PK parameters: maximum plasma concentration (Cmax), Maximum plasma concentration (Cmax) of SAR341402, NovoRapid and NovoLog within 12 hours, 12 hours|Assessment of PK parameters: Area under the concentration versus time curve (AUC), INS-AUC of SAR341402, NovoRapid, and NovoLog from 0 to 12 hours, 12 hours|Assessment of PK parameter: AUC from dosing to last concentration (AUClast), INS-AUClast is AUC from the time of dosing to the last measurable concentration of SAR341402, NovoRapid, and NovoLog from 0 to 12 hours, 12 hours|Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR), Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12), 12 hours | Secondary: Assessment of PK: Fractional area under the concentration versus time curve, INS-AUC0-2 and INS-AUC4-tlast, 12 hours|Assessment of PK: Time to 20 % of INS-AUC, Time to 20% of AUC (t20%-INS-AUC) within 12 hours, 12 hours|Assessment of PK: time to reach INS-Cmax (INS-tmax), INS-tmax within 12 hours, 12 hours|Assessment of PK: time to reach INS-t1/2z (INS-t1/2z), INS-t1/2z within 12 hours, 12 hours|Assessment of PD: Fractional area under the body weight standardized GIR versus time curve, GIR-AUC0-2 and GIR-AUC4-12, 12 hours|Assessment of PD: Time to 20 % of total GIR-AUC0-12h, Time to 20% of total GIR-AUC0-12h (t20%-GIR-AUC0-12h) within 12 hours, 12 hours|Assessment of PD: Maximum smoothed body weight standardized GIR (GIRmax), Maximum smoothed body weight standardized GIR (GIRmax) within 12 hours, 12 hours|Assessment of PD: Time to GIRmax (GIR-tmax), Time to GIRmax (GIR-tmax) within 12 hours, 12 hours|Number of adverse events (AEs), Number of patients with treatment emergent AEs and serious adverse events (SAEs), 8 weeks
|
